Star Combo Pharma’s FY26 results reveal a sharp 15% drop in group revenue and a steep fall in profit before tax, driven by a 10% decline in its core manufacturing segment and the closure of its retail division.
- 15% decline in total group revenue to $23.57 million
- Profit before tax down 90% to $528,472
- 10% revenue drop in core OEM manufacturing segment
- Retail division closed in November 2025
- Net tangible assets per share stable at $0.28
Revenue and Profit Take a Hit as Retail Business Shuts
Star Combo Pharma Ltd (ASX:S66) posted a sobering set of full-year results for FY26, with total group revenue slipping 15% to $23.57 million and profit before tax plunging by over 90% to just $528,472. The decline is largely attributed to a 10% fall in revenue from its core Original Equipment Manufacturing (OEM) and Own Brands segment, which dropped to $23.2 million from $25.8 million the previous year.
Contributing to the revenue contraction was the deliberate closure of Star Combo’s non-core retail operations, AustoYou and Koala Mall, which ceased trading in November 2025. The retail division’s revenue dwindled from $2 million in FY25 to a mere $378,624 in FY26 before shuttering completely, marking a strategic exit from this segment amid challenging economic conditions.
Operational Focus Shifts to Contract Manufacturing
Despite the revenue headwinds, the company highlighted ongoing efforts to expand its client base and develop new products within its manufacturing and distribution business. Star Combo is positioning itself as a leading contract manufacturer in Australia’s vitamin and health supplements sector, a strategy that underpinned its operational focus throughout FY26.
Distribution arrangements for proprietary brands like Living Healthy and Costar have strengthened domestically, with notable partnerships including Terry White Chemmart. The company also targets growth in Asian markets by catering to an expanding middle class and ageing populations, although longer-term contracts are yet to be secured.
Balance Sheet and Cash Flow Remain Solid
On the balance sheet front, net tangible assets per share edged up slightly to $0.28 from $0.27 in FY25, reflecting stability despite the profit squeeze. Cash and cash equivalents held steady at around $3.9 million, supplemented by term deposits of $14.1 million. The company invested $2.45 million in manufacturing facilities during the year, signaling continued capital commitment to its core operations.
Lease liabilities increased to $4.15 million, reflecting ongoing commitments related to its Smithfield manufacturing site, which the company values as a critical asset for future growth. The lease includes extension options, with management indicating no plans to vacate the premises in the near term.
Dividends and Governance
Star Combo declared $400,000 in franked dividends for FY26, down from $500,000 the previous year, maintaining a shareholder return despite the reduced earnings. The board, chaired by Richard Allely, remains stable with no changes to key management personnel reported post-year-end.
The company’s financial statements were audited without dispute, underscoring a clean governance record. Related party transactions included rental payments to Antoine International Pty Ltd, a related entity, totaling $419,000 for the year.
What Lies Ahead for Star Combo Pharma?
Star Combo’s FY26 results paint a mixed picture: the strategic retreat from retail has trimmed revenues but refocused the company on its manufacturing strengths. With economic headwinds dampening demand, the path to restoring growth hinges on securing new OEM contracts and expanding distribution both domestically and in Asia.
The sizeable investment in manufacturing infrastructure and the stable balance sheet provide a platform, but the company’s ability to convert its client expansion efforts into sustained revenue growth remains to be seen. Investors may watch closely for signs of recovery in OEM sales and the impact of lease commitments on cash flow in upcoming quarters.
Bottom Line?
Star Combo Pharma’s FY26 results reflect a strategic pivot and tough market conditions, raising questions about its ability to rebound in manufacturing revenue and leverage recent capital investments.
Questions in the middle?
- Will Star Combo’s OEM client expansion translate into meaningful revenue growth in FY27?
- How will the closure of the retail division impact the company’s overall profitability and cash flow going forward?
- What are the risks associated with the company’s lease obligations and capital expenditures amid a subdued operating environment?